Patient-centred care: The next generation of health reforms Mark Pearson, Directorate for Employment, Labour and Social Affairs 5 th OECD Parliamentary Days Paris, 9 February 2017
Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Patient-centred care:The next generation of health reforms
Mark Pearson, Directorate for Employment, Labour and Social Affairs
5th OECD Parliamentary DaysParis, 9 February 2017
On traditional measures, the difference between best and worst performers can be minimal…
Variation in clinics’ care for prostate cancer in Germany
… patient-reported outcomes, however, reveal huge differences in the quality of care.
Variation in clinics’ care for prostate cancer in Germany
The next generation of health reforms
At last one fifth of health spending in OECD countries is at best ineffective and at worst,
wasteful
• Adverse events in 1/10 hospitalisation, add between 13 and 17% to hospital costs and up to 70% could be avoided
• Geographic variations in rates of cardiac procedures (x3) and knee replacements (x5) are largely unwarranted
• 12% to 56% of emergency department visits inappropriate
• Share of generics varies between 10% and 80%
• Administrative expenditure varies more than seven-fold
• Loss to fraud and error averages 6% of payments
7
Inappropriate use of antibiotics by type of health care service is high, especially in general practice
Dialysis [3] Pediatric [9] Critical care [5] Ambulatory [4] Hospital/Tertiary [27]
Long-term care [13]
General practice [4]0
10
20
30
40
50
60
70
80
90
100
% In
appr
opria
te u
se
Estimates of the proportion of inappropriate use based on literature by service (range)Numbers in squared parentheses indicate the number of studies available
New Health Technologies:Managing access, value and sustainability
9
Right innovations: Number of new antimicrobials approved by the Food and Drug Administration since 1983
1983- 1988- 1993- 1992- 2003- 2008- 1987 1992 1997 2002 2007 2012
20
15
10
5
0
Year
Source: Adapted from Infectious Diseases Society of America, 2011 in Cecchini et al., 2015
10
Right prices: Cancer drug price per life year gained at approval in the United States (in 2013 USD)
Source: Howard et al., 2015
11
Right rewards:
http://www.oecd.org/health/biotech/
http://www.oecd.org/health/paris.htm
oe.cd/tackling-wasteful-spending-on-health
Contacts:[email protected]
Website: www.oecd.org/healthFollow us on Twitter: @OECD_Social
Read more about our work
Related Documents
